BTK and systemic lupus erythematosus: The fact that these immune cells play key roles in driving end organ inflammation in multiple systemic rheumatic diseases, and previous reports of BTK inhibition of lupus and rheumatoid arthritis (5–10), taken together, have broad implications for the use of BTKB66 in managing patients with systemic rheumatic diseases where multiple end organs are afflicted.